|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lam JS, Shvarts O, Leppert JT, Figlin RA
and Belldegrun AS: Renal cell carcinoma 2005: New frontiers in
staging, prognostication and targeted molecular therapy. J Urol.
173:1853–1862. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frank I, Blute ML, Cheville JC, Lohse CM,
Weaver AL and Zincke H: An outcome prediction model for patients
with clear cell renal cell carcinoma treated with radical
nephrectomy based on tumor stage, size, grade and necrosis: The
SSIGN score. J Urol. 168:2395–2400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun M, Shariat SF, Cheng C, Ficarra V,
Murai M, Oudard S, Pantuck AJ, Zigeuner R and Karakiewicz PI:
Prognostic factors and predictive models in renal cell carcinoma: A
contemporary review. Eur Urol. 60:644–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Volpe A and Patard JJ: Prognostic factors
in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shariat SF and Xylinas E: Biomarkers in
personalised treatment of renal-cell carcinoma. Lancet Oncol.
13:751–752. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou B and Gitschier J: hCTR1: A human
gene for copper uptake identified by complementation in yeast. Proc
Natl Acad Sci USA. 94:7481–7486. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee J, Prohaska JR, Dagenais SL, Glover TW
and Thiele DJ: Isolation of a murine copper transporter gene,
tissue specific expression and functional complementation of a
yeast copper transport mutant. Gene. 254:87–96. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu GF: Copper stimulates proliferation of
human endothelial cells under culture. J Cell Biochem. 69:326–335.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Díez M, Arroyo M, Cerdàn FJ, Muñoz M,
Martin MA and Balibrea JL: Serum and tissue trace metal levels in
lung cancer. Oncology. 46:230–234. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuo HW, Chen SF, Wu CC, Chen DR and Lee
JH: Serum and tissue trace elements in patients with breast cancer
in Taiwan. Biol Trace Elem Res. 89:1–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martin F, Linden T, Katschinski DM, Oehme
F, Flamme I, Mukhopadhyay CK, Eckhardt K, Tröger J, Barth S,
Camenisch G and Wenger RH: Copper-dependent activation of
hypoxia-inducible factor (HIF)-1: Implications for ceruloplasmin
regulation. Blood. 105:4613–4619. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li S, Zhang J, Yang H, Wu C, Dang X and
Liu Y: Copper depletion inhibits CoCl2-induced aggressive phenotype
of MCF-7 cells via downregulation of HIF-1 and inhibition of
Snail/Twist-mediated epithelial-mesenchymal transition. Sci Rep.
5:124102015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Narayanan GRBS, Vuyyuru H, Muthuvel B and
Natrajan Konerirajapuram S: CTR1 silencing inhibits angiogenesis by
limiting copper entry into endothelial cells. PLoS One.
8:e719822013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brewer GJ, Dick RD, Grover DK, LeClaire V,
Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, et al:
Treatment of metastatic cancer with tetrathiomolybdate, an
anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res.
6:1–10. 2000.PubMed/NCBI
|
|
18
|
Escudier B, Porta C, Schmidinger M,
Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V and Horwich A: ESMO
Guidelines Committee: Renal cell carcinoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27
Suppl 5:v58–v68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Buccheri G, Ferrigno D and Tamburini M:
Karnofsky and ECOG performance status scoring in lung cancer: A
prospective, longitudinal study of 536 patients from a single
institution. Eur J Cancer. 32:1135–1141. 1996. View Article : Google Scholar
|
|
21
|
Lopez-Beltran A, Bassi P, Pavone-Macaluso
M and Montironi R: Handling and pathology reporting of specimens
with carcinoma of the urinary bladder, ureter, and renal pelvis.
Eur Urol. 45:257–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z
and Xu J: Systemic inflammation score predicts postoperative
prognosis of patients with clear-cell renal cell carcinoma. Br J
Cancer. 113:626–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leibovich BC, Blute ML, Cheville JC, Lohse
CM, Frank I, Kwon ED, Weaver AL, Parker AS and Zincke H: Prediction
of progression after radical nephrectomy for patients with clear
cell renal cell carcinoma: A stratification tool for prospective
clinical trials. Cancer. 97:1663–1671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan D, Xu L, Liu H, Zhang W, Zhu Y, Xu J
and Gu J: Interleukin-11 receptor predicts post-operative clinical
outcome in patients with early-stage clear-cell renal cell
carcinoma. Jpn J Clin Oncol. 45:202–209. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu K, Xu L, Zhang L, Lin Z and Hou J: High
Jagged1 expression predicts poor outcome in clear cell renal cell
carcinoma. Jpn J Clin Oncol. 41:411–416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harrell FE Jr, Califf RM, Pryor DB, Lee KL
and Rosati RA: Evaluating the yield of medical tests. JAMA.
247:2543–2546. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Klomp AE, Tops BB, Van Denberg IE, Berger
R and Klomp LW: Biochemical characterization and subcellular
localization of human copper transporter 1 (hCTR1). Biochem J.
364:497–505. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Howell SB, Safaei R, Larson CA and Sailor
MJ: Copper transporters and the cellular pharmacology of the
platinum-containing cancer drugs. Mol Pharmacol. 77:887–894. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pourvali K, Matak P, Latunde-Dada GO,
Solomou S, Mastrogiannaki M, Peyssonnaux C and Sharp PA: Basal
expression of copper transporter 1 in intestinal epithelial cells
is regulated by hypoxia-inducible factor 2α. FEBS Lett.
586:2423–2427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gordan JD, Bertout JA, Hu CJ, Diehl JA and
Simon MC: HIF-2alpha promotes hypoxic cell proliferation by
enhancing c-myc transcriptional activity. Cancer Cell. 11:335–347.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brady DC, Crowe MS, Turski ML, Hobbs GA,
Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ and
Counter CM: Copper is required for oncogenic BRAF signalling and
tumorigenesis. Nature. 509:492–496. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bailey ST, Zhou B, Damrauer JS, Krishnan
B, Wilson HL, Smith AM, Li M, Yeh JJ and Kim WY: mTOR inhibition
induces compensatory, therapeutically targetable MEK activation in
renal cell carcinoma. PLoS One. 9:e1044132014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stassar MJ, Devitt G, Brosius M, Rinnab L,
Prang J, Schradin T, Simon J, Petersen S, Kopp-Schneider A and
Zöller M: Identification of human renal cell carcinoma associated
genes by suppression subtractive hybridization. Br J Cancer.
85:1372–1382. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xia Y, Liu L, Long Q, Bai Q, Wang J, Xu J
and Guo J: Decreased expression of CTR2 predicts poor prognosis of
patients with clear cell renal cell carcinoma. Urol Oncol.
34:5.e1–e9. 2016. View Article : Google Scholar
|
|
36
|
Ohrvik H, Nose Y, Wood LK, Kim BE, Gleber
SC, Ralle M and Thiele DJ: Ctr2 regulates biogenesis of a cleaved
form of mammalian Ctr1 metal transporter lacking the copper- and
cisplatin-binding ecto-domain. Proc Natl Acad Sci USA.
110:E4279–E4288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee YY, Choi CH, Do IG, Song SY, Lee W,
Park HS, Song TJ, Kim MK, Kim TJ, Lee JW, et al: Prognostic value
of the copper transporters, CTR1 and CTR2, in patients with ovarian
carcinoma receiving platinum-based chemotherapy. Gynecol Oncol.
122:361–365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsai CY, Liebig JK, Tsigelny IF and Howell
SB: The copper transporter 1 (CTR1) is required to maintain the
stability of copper transporter 2 (CTR2). Metallomics. 7:1477–1487.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Redman BG, Esper P, Pan Q, Dunn RL,
Hussain HK, Chenevert T, Brewer GJ and Merajver SD: Phase II trial
of tetrathiomolybdate in patients with advanced kidney cancer. Clin
Cancer Res. 9:1666–1672. 2003.PubMed/NCBI
|
